Featured Story | By Annalee Armstrong Editas' new CEO Gilmore O'Neill has already checked off a few items on his to do list in his first six weeks, including hiring a chief medical officer. Fierce Biotech caught up with him and his new CMO to find out what's next. read more |
| |
|---|
|
Top Stories By Gabrielle Masson Axel Hoos, M.D., Ph.D., left GSK almost a year ago, setting off to reinvent small-molecule drugs as CEO of Scorpion Therapeutics. It's a type of drug that's ripe for innovation, he figures, as other companies shift to new, hotter treatments like CAR-T. read more By Annalee Armstrong At the halfway point for the year, Fierce Biotech looks back at some of the most important layoff events that have hit the industry in 2021. read more By Annalee Armstrong Inovio is reducing its workforce by 18% in a restructuring that will extend the biotech’s cash runway into 2024 and allow for prioritization of its lead DNA medicine programs. The cuts are in concert with previously announced changes to the biotech’s troubled COVID program. read more By Annalee Armstrong Viking Therapeutics is relaunching the longship for a phase 1b metabolic disorder study six months after the FDA sidelined the vessel with a clinical hold. read more By Nick Paul Taylor Novartis has put a trio of midphase drugs up for partnering. After performing its annual portfolio review, the Swiss Big Pharma decided to bring in outside support to drive development of treatments for retinitis pigmentosa, asthma and nonalcoholic steatohepatitis. read more By Nick Paul Taylor Roche’s hunt for better eye disease gene therapy vectors has led it to Avista Therapeutics. In a heavily backloaded deal, the Swiss Big Pharma has offered up $1 billion to secure the right to assess and license AAV capsids developed by Avista. read more By Gabrielle Masson A glimpse at data for just 11 patients was enough to convince Ultragenyx Pharmaceutical that GeneTx Biotherapeutics is worth $75 million. After an interim data drop late Monday afternoon, Ultragenyx is exercising its right to acquire partner GeneTx. read more By Annalee Armstrong Sanofi is letting go of a genetic kidney disease therapy under development with Regulus Therapeutics after getting a peak at an interim analysis. Development will be shut down for the anti-microRNA 21 oligonucleotide lademirsen, which was being tested in patients with a genetic disease called Alport syndrome. read more By Gabrielle Masson Cartography Biosciences is putting its name on the map, exiting stealth mode with $57 million for an antigen atlas designed to direct scientists to more precise and effective immunotherapies. read more By Max Bayer,Annalee Armstrong PACT Pharma has let go of 94 employees, leaving remaining staff to work on two clinical stage assets in immuno-oncology, according to a state workforce report in California. read more By Fraiser Kansteiner Johnson & Johnson is no stranger to buyouts, with around half of the healthcare conglomerate’s pharma innovation sourced from outside the company, new CEO Joaquin Duato said on a call with analysts Tuesday. Now, as a consumer health spinoff looms, the helmsman is talking up M&A opportunities amid a sweeping biotech depression. read more By Conor Hale General Electric took another step forward in its plan to split up its businesses among a trio of independent, publicly traded companies. It has set out a road map into early 2024 and announced the brand names of its new scions focused on medical products, aviation and energy. read more By Dave Muoio New COVID-19 admissions numbers have been steadily increasing since early April and have doubled since early May, according to the CDC. read more |  | YOU vs. “UNSOLVABLE” PROBLEMS Let’s solve patient needs together. Turn promise into reality and become part of something bigger, today. Explore meaningful careers here. |
|---|
Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Lumanity Join us, as we explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene therapy space. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Decentralized Clinical Trials Forum July 26, 2022 | Free Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Health Payer Forum October 12, 2022 | Free Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Clinical Quality Oversight Forum: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia PA | Presented by: Fierce Pharma Decentralized Clinical Trials Summit: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia, PA | Presented by: Fierce Pharma Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Free Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual Fierce Clinical Trial Billing & Research Compliance Summit February 2023 | Location TBD Fierce BD&L Summit for Life Sciences March 14-15, 2023 | San Francisco, CA | 
